IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1080
Positioning
Market Dominance
Manufacturing
Medical Equipment
$53.4B
Thomas E. Polen
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis cathetters, vascular care and preparation products, needle-free IV connectors and extensions sets, syringes, pen needles, and other products for diabetes. Its Life Sciences segment provides specimen and blood collection products; other surgical products.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = BDX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$BDX BECTON DICKINSON & CO | 57 | 75 | 87 | 39 | 33.6x | 21.7x | 6.2% | 2.9% | 44.9% | 11.4% | 7.3% | 5.3% | 2.2% | 117.0x | $53.4B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
BECTON DICKINSON & CO (BDX) receives a "Hold" rating with a composite score of 56.6/100. It ranks #1080 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Thomas E. Polen
Chief Executive Officer
Labor Force
77,000
75
43
74
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for BDX
Headcount
77.0K
HQ Base
Franklin Lakes, New Jersey
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for BDX.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 75 | 83 | -8DRAG |
| MOMENTUM | 39 | 20 | +19ALPHA |
| VALUATION | 87 | 89 | -2NEUTRAL |
| INVESTMENT | 43 | 78 | -35DRAG |
| STABILITY | 74 | 72 | +2NEUTRAL |
| SHORT INT | 40 | 32 | +8ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 6.2% (sector -2.5%)
GM 45% vs sector 43%, OM 11% vs sector 1%
Capital turnover N/A, R&D intensity 5.8%
Rev growth 5%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns BECTON DICKINSON & CO a Hold rating, with a composite score of 56.6/100 and 3 out of 5 stars. Ranked #1080 of 7,333 stocks, BDX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
BDX earns a quality score of 75/100, indicating above-average business quality. The company reports a return on equity of 6.2% (sector avg: -2.5%), gross margins of 44.9% (sector avg: 42.5%), net margins of 7.3% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
BDX carries a solid value score of 87/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 33.65x, an EV/EBITDA of 21.68x, a P/B ratio of 2.09x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 43/100, BDX exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 5.3% vs. a sector average of 5.9% and a return on assets of 2.9% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
BDX is currently showing below-average momentum at 39/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 5.3% year-over-year, while a beta of 0.60 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
BDX shows good financial stability with a score of 74/100. Key stability metrics include a beta of 0.60 and a debt-to-equity ratio of 117.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 40/100 for BDX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 117.00x). With a $53.4B market cap (large-cap), BECTON DICKINSON & CO may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
BDX pays a solid dividend yield of 2.2%, contributing an income component to total returns. This moderate yield suggests a balance between returning capital to shareholders and retaining earnings for reinvestment — a common profile among quality compounders.
BECTON DICKINSON & CO is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1080 of 7,333 overall (85th percentile). Key comparisons include ROE of 6.2% exceeding the -2.5% sector median and operating margins of 11.4% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BDX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (87) vs Momentum (39) — closing this gap could shift the rating.
EV/EBITDA 89% ABOVE SECTOR MEDIAN
ROE 350% BELOW SECTOR MEDIAN
Gross Margin 6% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate BECTON DICKINSON & CO (BDX) as a Hold with a composite score of 56.6/100 at a current price of $182.90. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in value (87th percentile) and quality (75th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (39th percentile) and investment (43th percentile) tempers our overall conviction. We assign a No Moat rating (39/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
BECTON DICKINSON & CO holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 56.6/100 places it at rank #1080 in our full 7,333-stock universe. With a $53.4B market capitalization, BECTON DICKINSON & CO operates at meaningful scale within the Manufacturing sector, providing competitive advantages in distribution, procurement, and customer reach.
Revenue is growing at 5%, though momentum at the 39th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 45% (+2.4pp vs sector) narrow to operating margins of 11% (+10.1pp vs sector) and net margins of 7.3%, yielding a gross-to-net conversion rate of 16%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $182.90, BECTON DICKINSON & CO appears undervalued relative to its fundamentals. Our value factor score of 87/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at a P/E of 33.6x (a 51% premium to the sector median of 22.3x), EV/EBITDA of 21.7x (at a premium), P/B of 2.1x, P/S of 2.5x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
Gross margins of 45% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A value factor score of 87/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
A 2.23% dividend yield provides income while you wait, and dividends historically account for a significant portion of total equity returns.
Elevated leverage (117% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
We assign a Medium uncertainty rating to BECTON DICKINSON & CO. The stock presents a balanced risk profile: significant leverage (117% debt-to-equity) and low beta of 0.60 — while defensive, this may indicate limited upside participation in bull markets. While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: significant leverage (117% debt-to-equity); low beta of 0.60 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 74th percentile and quality factor at the 75th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 45% provide a buffer against cost pressures; above-average stability (74th percentile) suggests predictable business dynamics; large-cap scale ($53.4B) provides resilience. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate BECTON DICKINSON & CO's capital allocation as Poor. Key concerns include suboptimal returns on capital. Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — BECTON DICKINSON & CO significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, BECTON DICKINSON & CO receives a Hold rating with a composite score of 56.6/100 (rank #1080 of 7,333). Our quantitative framework assigns a No Moat (39/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 64/100.
Our analysis supports a neutral stance on BECTON DICKINSON & CO. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign BECTON DICKINSON & CO a meaningful economic moat, scoring 39/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 14.9/20.
The strongest moat sources are margin superiority (14.9/20) and growth durability (10.9/20). GM 45% vs sector 43%, OM 11% vs sector 1%. Rev growth 5%, 11yr history. These pillars form the core of BECTON DICKINSON & CO's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (2/20) and economic value creation (5.8/20). Capital turnover N/A, R&D intensity 5.8%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect BECTON DICKINSON & CO's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 45% providing a solid profitability foundation, operating margins of 11% reflecting effective cost management, moderate revenue growth of 5%. The margin cascade from 45% gross to 11% operating to 7.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 75th percentile.
The margin profile shows gross margins of 45%, operating margins of 11%, net margins of 7.3%. Return metrics include ROE of 6.2% and ROA of 2.9%. Relative to the Manufacturing sector, gross margins are 2.4 percentage points above the sector median of 43%, and ROE of 6.2% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 117%, a dividend yield of 2.23%, revenue growth of 5%. The sector median D/E is 0%, putting BECTON DICKINSON & CO at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Becton Dickinson & Co. (BDX) saw its stock rally by 2.99% to $182.68 on Wednesday, outperforming the broader market which also rose. This marks the second consecutive day of gains for the company's shares. The article highlights the stock's performance in comparison to the S&P 500 Index and the Dow Jones Industrial Average.

Becton, Dickinson and Company (BDX) is a strong player in the healthcare sector with a market cap of $67.17 billion, trading at $185.39 with a 5.39% potential upside according to analysts. The company exhibits financial stability with a 2.27% dividend yield and robust free cash flow, alongside bullish technical indicators. Despite conservative revenue growth, BDX's commitment to innovation and diverse product offerings position it as an attractive investment for stability, income, and moderate growth.

Ocular Therapeutix reported positive topline results for its AXPAXLI (OTX-TKI) in the SOL-1 Phase 3 superiority trial for wet AMD. The trial successfully met its FDA-aligned primary endpoint at Week 36, demonstrating that 74.1% of subjects maintained vision, and showed durable Week 52 outcomes with 65.9% maintaining vision, surpassing aflibercept. Despite these strong clinical results, the market reacted negatively, with Ocular Therapeutix (NASDAQ: OCUL) stock declining by 21.28% on the news day.
The global hemostats market is projected to grow from USD 4.75 billion in 2023 to USD 7.94 billion by 2030, exhibiting a CAGR of 7.6%. This growth is driven by the increasing prevalence of chronic diseases and surgical procedures, as well as innovations and regulatory approvals for new products. North America currently dominates the market, with Europe following, while significant market contenders are emerging through strategic mergers and acquisitions.

BD (Becton, Dickinson and Company) has appointed Lanesha Minnix as Executive Vice President and General Counsel, effective March 16, 2026. Minnix, who previously held senior legal roles at Walgreens Boots Alliance where she played a key part in a $24 billion take-private transaction, will lead BD's Law Group and Public Affairs and join the Executive Leadership Team. This appointment comes as BD navigates significant strategic changes, including portfolio adjustments and debt management.